Visiogen, Inc. Receives FDA Approval To Expand Its U.S. Clinical Trial

IRVINE, Calif.--(BUSINESS WIRE)--Visiogen, Inc. of Irvine, California, announced it has received approval from the U.S. Food & Drug Administration (FDA) for full expansion of its Phase III U.S. clinical trial for its Synchrony® dual optic accommodating intraocular lens. Already approved for use throughout the European Union, the Synchrony system is being studied in a multi-center trial in the U.S. to evaluate safety and effectiveness and the potential for near and intermediate vision without the use of spectacles in patients post cataract surgery.

Back to news